Literature DB >> 2116258

Benefits, risks, and costs of prescription drugs: a scientific basis for evaluating policy options.

G M Anderson1, W O Spitzer, M C Weinstein, E Wang, J L Blackburn, U Bergman.   

Abstract

Mesh：

Year:  1990        PMID： 2116258     DOI： 10.1038/clpt.1990.125

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  5 in total

1.  Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.

Authors:  D Henry
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

2.  Dynamic competition as an exploratory model of healthcare policy for the antihypertensive market.

Authors:  R J Bonk; M J Myers; C H Knowlton; D Sabapathi; W F McGhan
Journal:  Pharmacoeconomics       Date:  1996-09       Impact factor: 4.981

Review 3.  The societal value of pharmaceuticals. Balancing industrial and healthcare policy.

Authors:  J Grund
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

4.  Prescribing patterns among medical practitioners in Pune, India.

Authors:  M J Kshirsagar; D Langade; S Patil; P S Patki
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

5.  Drug expenditures in a balanced strategy for healthcare policy.

Authors:  R J Bonk; M J Myers; W F McGhan
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.